


The slide features a blue background with white diagonal lines. In the top left corner is the PDA logo with the tagline "Connecting People, Science and Regulation". In the top right corner is the PIC/S logo. The main title "ICH Q7 Chapter 11: Laboratory Control" is centered in white. To the right of the title are three circular images: a laboratory machine, a person in a lab coat and mask, and a close-up of a syringe. At the bottom left, it says "PDA - PIC/S ICH Q7 Training 01/2014".

PDA  
Connecting People, Science and Regulation

PIC/S

# ICH Q7 Chapter 11: Laboratory Control

PDA - PIC/S  
ICH Q7 Training 01/2014



The slide has a blue header with the PDA logo on the left and the PIC/S logo on the right. The text "ICH Q7 Training Chapter 11: Laboratory Controls" is centered in the header. The main content area is white with the title "Disclaimer" in bold. Below the title is a bulleted list of three items. The first two are black text, and the third is blue text with a diamond bullet. At the bottom left is the PDA tagline, and at the bottom right is the number "2".

PDA  
Connecting People, Science and Regulation

ICH Q7 Training  
Chapter 11: Laboratory Controls



PIC/S

## Disclaimer

- The slides set is based on the training sessions developed and performed by the members of the ICH Q7 Expert Working Group (EWG) on ICH Q7 2001/2002
- The slides have been updated 2012 and represents the views of the PDA / PIC/S committee for the purposes of a general training for regulators and industry.
- ◆ *We focused on elements in ICH Q7 where further explanation and/or clarification is useful.*

Connecting People, Science and Regulation®



2

 ICH Q7 Training  
Chapter 11: Laboratory Controls 

## Content


- **General Controls (11.1)**
- **Testing Intermediates & APIs (11.2)**
- **Validation Analytical Procedures (11.3 / 12.8)**
- **Certificates of Analysis (11.4)**
- **Stability Monitoring (11.5)**
- **Expiry & Retest Dating (11.6)**
- **Reserve / Retention Sample (11.7)**

Connecting People, Science and Regulation® 3


 ICH Q7 Training  
Chapter 11: Laboratory Controls 


## Laboratory Controls

**Not appreciably  
different from  
expectations for  
laboratories that test  
medicinal products**




Connecting People, Science and Regulation® 4


 ICH Q7 Training  
 Chapter 11: Laboratory Controls





## 11.1 General Controls

- **Scope**
  - Raw materials
    - API starting materials
    - Reagents
    - Solvents
    - Process aids
  - Intermediates
  - APIs ◆ (*commercial supply, retained, stability samples*)
  - Packaging materials




Connecting People, Science and Regulation® 5


 ICH Q7 Training  
 Chapter 11: Laboratory Controls



## 11.1 General Controls

- **Documented procedures for (11.11)**
  - Sampling
  - Testing
  - Approval / Rejection
  - Recording Data
  - Storing Data
  - ◆ *Audit trail and data integrity must be given*
  - Out of Specification (OoS) results documented & justified



Connecting People, Science and Regulation® 6




## 11.1 General Controls

- **Specifications, sampling plans, test procedures (11.12)**
  - Appropriate and scientifically sound
    - To ensure conformance to established standards
  - Prepared by appropriate unit
  - Reviewed and approved by Quality Unit(s)
  - Specifications and test procedures should be consistent with those in registration file
  - There can be specifications in addition to those in registration




## 11.1 General Controls

- **API specifications (11.13)**
    - Include control of impurities
      - Organic, inorganic, residual solvents, ...
    - If API has specifications for microbiological purity, appropriate action limits established for
      - Total microbial count
      - Objectionable organisms
    - If API has specifications for endotoxins, appropriate action limits established
- ◆ *Consider Pharmacopieal monograph guidance depending on the nature of the drug product*




ICH Q7 Training  
Chapter 11: Laboratory Controls




## 11.1 General Controls

- **Documented at time of performance (11.14)**
  - ◆ *Quality systems should be capable of monitoring occasions where records are not completed at the time activities are performed*
- **Departures from procedures documented and explained (11.14)**

Connecting People, Science and Regulation® 9



ICH Q7 Training  
Chapter 11: Laboratory Controls



## 11.1 General Controls

- **Out of Specification (QoS) results (11.15)**
  - Procedure for investigation & documentation, including
    - Analysis of data
    - Assessment of significance of problem
    - Allocation of corrective action tasks
    - Conclusions
  - ◆ *The quality assurance should be involved in the assessment and review of the OoS before batch release*
  - Resampling / retesting performed according to procedure
    - ◆ *Re-sampling / Retesting plans and conclusions should be based on a scientific justification*

Connecting People, Science and Regulation® 10



## 11.1 General Controls

- Reagents and standard solutions should be prepared and labeled following written procedures (11.16)
- “Use by” dates should be applied as appropriate (11.16)

◆ *It is **not** usual to have formal testing program to establish ‘use by’ date. Experience and scientific judgment is usually adequate. Supplier instructions should be followed at least.*



11



## 11.1 General Controls

- **Primary standard** (11.17)
  - Obtained from a recognized source
    - If official source: does not need to be tested
  - “In-house primary standard” (11.18)  
Prepared by independent synthesis or by further purification of existing production material or by use of a routine batch of adequate quality
    - This should be supported by an additional set of analytical tests, showing authentic material of established quality

◆ *It is best practice that this test typically should include an alternative test to quantify the purity*

12



## 11.1 General Controls



- **Secondary standard (11.19)**
    - A substance of established quality, as shown by comparison to a primary standard
    - Used as a reference standard for routine laboratory analysis (working standard)
    - Each batch of secondary standard compared to primary standard prior to first use
    - Periodically requalified according to written protocol
- ◆ *To define the periodicity depends on e.g. stability, storage conditions*



## 11.2 Testing APIs & Intermediates

- **Each batch - appropriate tests conducted to determine conformance to specifications (11.20)**
    - Should be in compliance with registration
- ◆ *May be appropriate not to do complete testing after each step e.g. after blending, milling for parameters which had been demonstrated that they would not be affected*






 ICH Q7 Training  
 Chapter 11: Laboratory Controls
 

## 11.2 Testing APIs & Intermediates

- **Impurity** (see also ICH Q3/M7 series)
  - An impurity is any component present in the intermediate or API that is not the desired entity
    - Residual Solvents (ICH Q3C)
    - Degradants
    - Water
    - Reactants
    - Metals (ICH Q3D)
    - Intermediates
    - Salts
    - Catalysts
    - Organics
    - Ligands
    - Genotoxic (ICH M7)
    - Process Aids
    - Byproduct

Impurities

Connecting People, Science and Regulation®
15


 ICH Q7 Training  
 Chapter 11: Laboratory Controls
 

## 11.2 Testing APIs & Intermediates

- **Impurity profile (identified and unidentified) for API should be established (11.21)**
  - Identity (or some qualitative analytical designation)
  - Range observed
  - Classification (inorganic, organic, solvent, etc)
- **Impurity profile is for typical batch produced by specific controlled production process (11.21)**
  - ◆ *Biotech APIs are covered in ICH Q6B*
  - ◆ *API manufacturing which do not include chemical synthesis (e.g. from herbal or animal tissue source) this is not always relevant*

Connecting People, Science and Regulation®
16





## 11.2 Testing APIs & Intermediates

- **Impurity profile for API (11.22)**
  - Compared at appropriate intervals versus profile in regulatory submission or historical data
    - ◆ *e.g. by online trending or the product quality review*
  - To detect changes resulting from modifications in raw materials, equipment operating parameters, production process
- **Appropriate microbiological tests on intermediates and APIs where defined microbial quality is specified (11.23)**





## 12.8 Validation of Analytical Methods

- **Methods should be validated (12.81)**
- **Suitability of all methods should be verified under actual conditions of use and documented (12.80)**
  - ◆ ... where a Pharmacopeial method is used



ICH Q7 Training  
Chapter 11: Laboratory Controls



## 12.8 Validation of Analytical Methods

- **Degree of validation should reflect purpose of analysis and stage of API production process (12.81)**

<p>◆ <b>Typically 'Fit for purpose' methods</b> (demonstrating realistic results)</p> <ul style="list-style-type: none"> <li>- Raw materials</li> <li>- Solvents</li> <li>- Packaging materials</li> <li>- In process controls (IPC)</li> </ul>	<p><b>Typically requires analytical method validation</b> (according ICH Q2 A/B, Q6A/B)</p> <ul style="list-style-type: none"> <li>- API Starting material</li> <li>- Intermediates (exceptions for some non isolated intermediates)</li> <li>- API</li> </ul>
---	--

Connecting People, Science and Regulation® 19


ICH Q7 Training  
Chapter 11: Laboratory Controls


## 12.8 Validation of Analytical Methods

- **Validation should include consideration of characteristics included in ICH guidelines (12.81)**  
(ICH Q2A & Q2B)
- **Analytical equipment appropriately qualified before methods validation (12.82)**
- **Records maintained for modifications of validated methods, including (12.83)**
  - Reason for modification
  - Appropriate data to verify results are as accurate and reliable as established method

Connecting People, Science and Regulation® ◆ follow the change control procedure and consider the need for revalidation 20



ICH Q7 Training  
Chapter 11: Laboratory Controls




## 11.4 Certificates of Analysis (CoA)


- **Information on CoA & Label (11.41)**
  - Name
  - Grade (where appropriate)
  - Batch No.
  - Release Date
    - ◆ *The date of manufacturing is typically expected*
    - ◆ *Expiry date on the CoA & label*
    - ◆ *Retest date on the CoA and/or label*

Connecting People, Science and Regulation®

21



ICH Q7 Training  
Chapter 11: Laboratory Controls



## 11.4 Certificates of Analysis (CoA)

- **Information on CoA (original manufacturer) (11.43)**
  - Each test with acceptance limits & numerical results
    - ◆ *...rather than 'conform with specification' (exception e.g. IR)*
    - ◆ *The results reports should be inline with analytical method validation reporting e.g. 'less than limit of detection'*
  - Dated & signed by authorized quality personnel
  - Name, address, phone of original manufacturer
    - ◆ *Note the actual manufacturing site address not company only*

Connecting People, Science and Regulation®

22



## 11.4 Certificates of Analysis (CoA)

- **Information on CoA (repacker/reprocessor)**

(11.44)

- Name, address, phone of repacker / reprocessor
- Reference to original manufacturer
- Original CoA attached

◆ *Transcriptions should be clearly identified as such but not replacing the original*




## 11.5 Stability Monitoring of APIs

- **Documented on-going program** (11.50)

◆ *Be compliant with the registration*

- **Monitoring to confirm** (11.50)

- Appropriate storage conditions
- Retest / expiry dates



- **Validated stability indicating test procedures** (11.51)

◆ *Pharmacopeia test are not necessarily indicating stability*

- **Samples in simulated market container (material composition)** (11.52)



## 11.5 Stability Monitoring of APIs

- **First 3 commercial batches (normally)** (11.53)
  - If stable for 2 years, fewer may be used
- **Thereafter: 1 batch / year (if produced)** (11.54)
  - ◆ *For routine stability studies (monitoring) there is an expectation for studies to be conducted at long term conditions and not accelerated storage*
- **Tested annually (at least)** (11.54)
- **API with short shelf-life, more frequent testing** (11.55)
- **Consistent with ICH guidelines on stability storage conditions (as appropriate)** (11.56)
  - ◆ *Traditional validation, reprocessed / reworked (14.31), blending (8.46), repacked (17.50) batches are usually expected to put in stability*



## 11.6 Expiry & Retest Dating

- **Based on data from stability studies** (11.61)
- **Preliminary dates may be based on pilot scale batches if** (11.62)
  - Manufacture simulates commercial scale
  - Quality represents commercial scale material



## 11.6 Expiry & Retest Dating

- ◆ **Retest Date** - date when material should be re-examined to ensure still suitable for use under defined storage conditions
- ◆ **Expiry Date** - date designating time during which material expected to remain within specs if stored under defined conditions, and after which it should not be used
- ◆ ICH Q7 does not include guidance regarding user re-assigning retest date
  - Retest prior to use is commonly applied usually within 90 days after retesting



## 11.6 Expiry & Retest Dating

- **Intermediates**
  - If with an expiry/retest date assigned and
  - If intended to be transferred outside manufacturer's material management system
  - Supporting stability information should be available
- ◆ This does not require a stability monitoring program
- ◆ Could use initially published data. However retesting on actual product manufactured would typically be good practice



## 11.7 Reserve / Retention Samples

**For potential future evaluation of quality if necessary - not for stability testing purposes (11.70)**

- API with expiry date - keep longer of 1 year after expiry or 3 years after distribution (11.71)
- API with retest date - keep 3 years after distribution (11.71)

◆ *The availability of the API retain sample has to be considered between API and (typically) the drug product manufacturer*



## 11.7 Reserve / Retention Samples

**For potential future evaluation of quality if necessary - not for stability testing purposes (cont'd) (11.72)**

- Stored in same, equivalent or more protective packaging material than marketed package
- Sufficient sample for at least 2 full compendial / specification analyses

◆ *The samples are stored in an at least monitored environment*





## Key Messages

- **Expectation not appreciably different from expectations for laboratories that test medicinal products (e.g. Standards, OoS)**
- **Management of reference standards**
- **Clarity and integrity of raw data**
- **Methods validated or fit for purpose**
- **Expiry & Retest Dating based on data from real time stability studies**



## Acknowledgement

- **This version represents an update of the 2001/2002 version by ICH Q7 EWG members organised in a joint initiative between PDA and PIC/S developed in 2012**
  - Stephan Rönninger (co-chair)
  - Mikael Le Bihan (co-chair)
  - Karl-Heinz Bender
  - Rosimeire Pereira Alves da Cruz
  - Graeme McKilligan
  - Jacques Morenas
  - Edwin Rivera
  - Georg Roessling
  - Lionel Viornerwith input from members of the PIC/S Q7 expert cycle and other PDA volunteers

